Ureaplasma: What It Is, When It Matters, and India Testing Guide

• Ureaplasma colonises the genital tract of roughly 40 to 80 percent of healthy, sexually active adults. A positive test usually means harmless colonisation, not disease.
• Major bodies including NACO, the CDC, FOGSI, ASRM and ESHRE advise against routine, universal ureaplasma screening in people without symptoms.
• It can genuinely cause disease in specific situations: persistent urethritis in men, some pregnancy complications such as chorioamnionitis and preterm labour, and infections in very premature babies.
• Because it has no cell wall, penicillins and other beta-lactam antibiotics do not work. Treatment uses doxycycline, azithromycin or, in resistant cases, moxifloxacin.
• Test for the common causes first (chlamydia, gonorrhoea, BV, candida, trichomonas). Only consider ureaplasma when symptoms persist despite proper treatment of those.
• If treated, both partners are usually treated, and the result rarely needs to be read as a sexual-fidelity issue given how common colonisation is.

• No cell wall — penicillins and cephalosporins do not work against it.
• Two relevant species: U. urealyticum (often considered more pathogenic) and U. parvum.
• Found in 40 to 80 percent of sexually active adults, usually without any symptoms.
• Hard to culture; PCR is the usual modern test.

• Burning during urination
• Burning or pain during sex
• Unusual or increased vaginal discharge
• Thin urethral discharge (more typical in men)
• Mild pelvic or testicular discomfort
• Often, no symptoms at all

This is where a lot of anxiety and confusion sits. Some studies link ureaplasma to reduced fertility, IVF failure and miscarriage; others find no real connection. The conflict exists largely because so many healthy people carry ureaplasma anyway, making it very hard to separate a true effect from chance.

Because of this, ASRM and ESHRE do not recommend routine ureaplasma screening for all infertile couples — the evidence simply does not support universal benefit. Testing may be considered in specific situations such as repeated IVF failure with no other cause, recurrent pregnancy loss (two or more miscarriages), chronic endometritis seen on biopsy, or persistent genital symptoms during a fertility workup. If you are early in this journey, our overviews of what causes infertility and unexplained infertility put ureaplasma in proportion alongside the bigger drivers.

When ureaplasma is found, treatment (usually doxycycline or azithromycin for both partners) is straightforward, but whether it improves fertility outcomes is genuinely uncertain. A Cochrane review of antibiotic treatment around IVF found insufficient evidence to recommend it routinely.

In India, several private IVF networks include ureaplasma and mycoplasma testing in their pre-IVF or recurrent-failure workups, even though universal screening is not evidence-based. A single PCR test typically costs around Rs 1,500 to Rs 5,000 at private labs, or is bundled into a workup package. If you are weighing up treatment, our breakdown of IVF cost, process and success rates in India covers what is and is not worth paying for.

Pregnancy is the one area where the case for ureaplasma being clinically important is stronger. The bacterium can ascend from the lower genital tract into the uterus and cause chorioamnionitis (infection of the membranes and fluid around the baby). This is linked to preterm labour, preterm premature rupture of membranes (PPROM), and infections in newborns. Ureaplasma is, in fact, the organism most often recovered from amniotic fluid in preterm PPROM, and the association is strongest with very early (under 28 weeks) preterm birth.

Even so, ACOG, RCOG, FIGO and FOGSI do not recommend routine ureaplasma screening in pregnancy, because antibiotic-treatment trials have not consistently reduced preterm birth. Testing is generally reserved for specific scenarios: PPROM, suspected chorioamnionitis (fever, uterine tenderness, fast maternal or fetal heart rate), preterm labour, or a history of recurrent preterm birth.

When treatment is used, it is a pregnancy-safe macrolide such as azithromycin or erythromycin. Erythromycin is already part of the standard PPROM antibiotic regimen recommended by ACOG and RCOG, partly because it covers ureaplasma. In premature babies, ureaplasma is a recognised cause of neonatal pneumonia and sepsis and is managed by neonatal intensive care teams. If you are pregnant and noticing a sudden gush or persistent leak of fluid, read our guide on watery discharge in pregnancy and when it signals PPROM and contact your doctor.

• Persistent non-gonococcal, non-chlamydial urethritis in men after standard STI treatment.
• Recurrent urinary symptoms in women when urine cultures repeatedly grow no typical bacteria.
• Abnormal discharge that has not responded to treatment for BV, candida or trichomonas.
• Specific fertility scenarios: recurrent IVF failure, recurrent pregnancy loss, severe male-factor infertility, or chronic endometritis.
• Pregnancy complications: PPROM, suspected chorioamnionitis, or recurrent preterm birth.
• Workup of a sick premature newborn when no usual pathogen is found.

It is just as important to know when a ureaplasma test will only cause harm. Guidelines advise against testing in these situations:

• Healthy people with no symptoms, as part of a general health check.
• Routine pre-marital or pre-conception screening with no specific indication.
• Routine pregnancy screening.
• Before you have ruled out the far more common causes of your symptoms.

• Ureaplasma PCR (single): roughly Rs 1,500 to Rs 5,000.
• Combined Ureaplasma plus Mycoplasma genitalium PCR: roughly Rs 2,500 to Rs 8,000.
• Comprehensive STI panel (chlamydia, gonorrhoea, trichomonas, herpes, HIV, syphilis, hepatitis B and C, plus mycoplasma/ureaplasma): roughly Rs 5,000 to Rs 15,000.
• Home sample collection: usually Rs 200 to Rs 500 extra.

Because ureaplasma has no cell wall, treatment relies on antibiotics that work in other ways. Treatment is only given when there is a real clinical reason, not simply because a test was positive.

Doxycycline 100 mg twice daily for 7 to 14 days is a standard first-line option, sold in India under names like Doxt and Microdox for roughly Rs 30 to Rs 100 a course. Take it with food to reduce nausea and use sun protection, as it increases photosensitivity. It must not be used in pregnancy or in children under 8.

Azithromycin (1 g single dose, or 500 mg on day 1 then 250 mg daily for 4 more days) is an alternative, sold as Azithral or Azee, and is generally considered safe in pregnancy.

Moxifloxacin 400 mg daily for 7 to 10 days is reserved for resistant cases, as it has more side effects.

Resistance is a growing concern. Macrolide (azithromycin) resistance is rising worldwide and doxycycline resistance is also reported, so persistent symptoms after treatment should prompt retesting rather than repeated guessing — the same problem we describe for gonorrhoea's rising drug resistance. If treatment is given, partners are usually treated too, sexual contact is avoided until both finish the course plus 7 days, and a test of cure is done in pregnancy or fertility contexts. Avoid the classic errors: never use amoxicillin or cephalexin (they cannot work here), never cut the course short, and never treat without a proper diagnosis.

A positive result is common and rarely an emergency. Work through it calmly:

1. Look at the context. No symptoms and no specific reason for testing usually means harmless colonisation, and treatment is often not needed. Persistent unexplained symptoms, a fertility workup, recurrent pregnancy loss, or pregnancy complications make treatment more likely to be worthwhile.

2. Partners. If you are treated, your partner is usually treated at the same time to prevent re-infection, with both avoiding sex during treatment plus 7 days.

3. Retesting. A test of cure (about 3 to 4 weeks after finishing antibiotics) is reserved for persistent symptoms, pregnancy or fertility situations, not routine cases.

4. Address the bigger picture. Make sure the original reason for testing is followed up — whether that is symptom resolution, a fertility plan, or obstetric care.

5. Don't panic, and don't catastrophise the relationship angle. Because ureaplasma colonises so many healthy people, a positive result is not a reliable sign of recent sexual transmission or infidelity, unlike a clear-cut STI such as chlamydia or gonorrhoea. If you do need to discuss results with a partner, our guide on talking about STIs with partners can help frame the conversation without shame.

• Burning, abnormal discharge or pelvic pain that is not improving — to test for the common causes first.
• Persistent genital symptoms after you have already been treated for chlamydia, gonorrhoea, BV, candida or trichomonas.
• Recurrent urinary symptoms when cultures keep coming back clear.
• Repeated miscarriage, recurrent IVF failure, or chronic endometritis under investigation.
• Pregnancy with fever, uterine tenderness, a gush of fluid (possible PPROM), or signs of preterm labour — seek care urgently.
• A premature newborn with breathing difficulty or signs of infection — this is a neonatal emergency.

• CDC — Sexually Transmitted Infections Treatment Guidelines, 2021 (Mycoplasma and Urethritis)
• National AIDS Control Organisation (NACO), India — STI/RTI Services and Guidelines
• ACOG — Prelabor Rupture of Membranes (PPROM) Practice Bulletin
• BASHH (UK) — Mycoplasma genitalium Management Guidelines
• Cochrane — Antibiotic therapy for couples with infections in assisted reproduction
• WHO — Guidelines for the Management of Sexually Transmitted Infections